Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
04 November 2024
Name: | HEALTH HOUSE INTERNATIONAL LIMITED (HHI) | ||||||||||||
ISIN: | AU000000VPC3 | ||||||||||||
Date of Listing: | 28 July 2011 | ||||||||||||
Date of Delisting: | 18 May 2023 | ||||||||||||
Former Names: |
|
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 18 May 2023.Legal Status:
To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. We have not therefore verified the current legal status of this entity. If you have questions about your shareholding, as we say elsewhere, they may be taken up here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.Capital Gains Tax (CGT) Status:
To our knowledge this entity was the subject of a takeover or merger such that your securities were acquired for consideration in the form of cash or scrip. You will need to seek independent tax advice in relation to Capital Gains Tax or other tax matters but any other enquiries relating to your shareholding in the company should be followed up via our online form here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
Company | FROM | TO |
---|---|---|
HEALTH HOUSE INTERNATIONAL LIMITED | 24/03/2021 | |
VPCL LTD | 01/10/2018 | 24/03/2021 |
VELPIC LIMITED | 02/10/2015 | 01/10/2018 |
INTERNATIONAL COAL LIMITED | 02/10/2015 |
REGISTRY:
Link Market Services Brisbane
Level 21, 10 Eagle Street
Brisbane QLD 4000
Tel : +61 7 3320 2200 or 1300 554 474
Fax : +61 2 9287 0303
RegistryWebsite RegistryEmail
delisted at entity's request under Listing Rule 17.11 | 18/05/2023 |
we understand Creso Pharma Limited acquire all of the issued shares in HHI with HHI shareholders receiving 1 Creso Consideration Share and 0.25 Creso Consideration Options for every 2.9 HHI shares held by them | 18/05/2023 |
The company releases a notice of application for quotation of securities. | 08/05/2023 |
The company releases a notice of proposed issue of securities. | 08/05/2023 |
The securities of Health House International Limited will be suspended from quotation at the close of trading on Friday, 5 May 2023 under Listing Rule 17.2, following lodgement of the Supreme Court of Western Australia orders with ASIC approving the scheme of arrangement by which Creso Pharma Limited will acquire all of the issued shares in HHI. | 05/05/2023 |
The suspension of trading in the securities of Health House International Limited will be lifted from the commencement of trading on Monday, 13 March 2023 following lodgement of its half-year report and Appendix 4D. | 10/03/2023 |
The company lodges its Appendix 4D & FY23 Interim Financial Report. | 10/03/2023 |
The entity's securities will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Wednesday, 1 March 2023, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office yesterday and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/03/2023 |
The suspension of trading in the securities of Health House International Limited will be lifted from the commencement of trading on Friday, 23 December 2022 following lodgement of its Annual Report to Shareholders and Appendix 4G. | 22/12/2022 |
The company lodges the following: Annual Report to shareholders and Appendix 4G. | 22/12/2022 |
The company lodges its Appendix 4C Cash Flow Report. | 24/11/2022 |
The company lodges its September 2022 Quarterly Report. | 24/11/2022 |
Integration of Health House continues with acquisition to considerably increase revenue. Creso Pharma and Health House International management continue to work towards integration. Funds transferred to relinquish HHI of Zelira debt ahead of acquisition. HHI expected to considerably increase Creso Pharma's revenue profile. Inclusion of HHI's revenue implies a pro forma Creso unaudited last quarter annualized gross revenue (based on 30-Sep-22 quarter) of approximately A$24m (based on Creso revenues and entire quarter of SSH and HHI revenues). Product registration in South Korea underpins international expansion. | 23/11/2022 |
Inclusion of HHI's revenue implies a pro forma Creso unaudited last quarter annualized gross revenue (based on 30-Sep-22 quarter) of approximately A$24m (based on Creso revenues and entire quarter of SSH and HHI revenues). Scheme Implementation Deed signed to acquire Health House International for total value of up to approximately $4.6m, based on a Creso share price of A$0.043 per share. Health House is an international pharmaceutical distributor, specialising in the sale and distribution of medicinal cannabis products across Australia and the UK. Provides Creso Pharma with another revenue generating operating division and considerably increases the Company's global footprint. HHI generated $15,644,524 in revenue during FY22 (ending 30-Jun-22) "“ an 85.1% increase on FY2021 (FY2021: $8,449,564) and a 161.6% rise on FY2020 (FY2020:$5,978,940). Cost reduction opportunities across HHI are apparent "“ Health House is expected to benefit from shared group services, allowing for steep reductions in corporate costs in HHI. HHI recently completed the sale of CanPharma, eliminating an underperforming asset and its associated liabilities "“ removes actual and contingent liabilities of ~€2,887,000 (A$4,456,000) from HHI's balance sheet. Additional cross-selling opportunities, including the import of Mernova Medicinal Inc.'s premium cannabis product to Australia to potentially assist in fast tracking cash flow breakeven. Acquisition reiterates Company strategy of assembling a strategic portfolio of businesses and brands that have complementary strengths across manufacturing, processing, formulation, sales and distribution. Management intends to review further M&A opportunities. | 21/11/2022 |
Zelira Therapeutics y has agreed with Health House Limited and Creso Pharma Limited for the repayment of the previous working capital facility loan that Zelira had provided to Health House as follows: Creso, on behalf of Health House will make an immediate cash payment of $550,000 to Zelira; and Subject to shareholder approval on or prior to 31 December 2022, Creso agrees to issue to Zelira (or its nominee) that number of Creso Shares equal to $800,000 divided by the closing price of Creso's ordinary shares as traded on ASX the day prior to the Shareholder Meeting. Zelira is pleased advise it has now received an amount of $550,000 under this agreement. | 21/11/2022 |
Health House has entered into a scheme implementation deed with Creso Pharma Limited. Creso loan facility increased to $3,400,000. | 21/11/2022 |
The company announces the completion of the sale of CanPharma GmbH to Ms Sabine Jacker following the satisfaction of all conditions precedent. The sale of CanPharma removes actual and contingent liabilities of approx. €2,887,000 (AUD$4,456,000) from the Health House group's balance sheet. The sale of CanPharma will have no impact on the arrangement agreed between Health House and Creso Pharma Limited. | 16/11/2022 |
The company has executed a binding terms sheet with Ms Sabine Jacker for the sale all of the outstanding common shares of wholly-owned German subsidiary CanPharma GmbH. The sale of CanPharma will have no impact on the arrangement agreed between Health House and Creso Pharma Limited. | 01/11/2022 |
The company intends to hold its AGM on 28 November 2022. Any nominations for directors must be received at the company's registered office no later than 5.00pm (Perth time) on 10 October 2022. | 03/10/2022 |
The securities of the company will be suspended from Official Quotation in accordance with Listing Rule 17.5 from the commencement of trading today, 3 October 2022, following their failure to lodge the relevant periodic report by the due date. | 03/10/2022 |
The suspension of trading in the securities of Health House International Limited will be lifted immediately following the release by HHI of an announcement. | 09/09/2022 |
Following execution of the Loan Facility Agreement with Creso Pharma Limited and the Convertible Note, announced on 5 September 2022, the Health House voluntary suspension will be lifted. | 09/09/2022 |
Zelira Therapeutics has agreed with Health House to extend the date for repayment of its short-term loan provided by ZLD in February 2022 to 31 October 2022, subject to Health House paying an amount of $400,000 immediately. Zelira has now received an amount of $400,000 from Health House. The balance of the loan, including calculated interest is now repayable by 31 October 2022, pursuant to the terms of the Zelira working capital facility loan agreement announced to the market on February 24, 2022. | 08/09/2022 |
The company releases an Appendix 3G. | 05/09/2022 |
Creso has significantly advanced its due diligence on the proposed acquisition of Health House. Work to date included an analysis of HHI's revenue base, following HHI's generation of A$15.2m of cash receipts for the 12 months ended 30 June 2022 as well as opportunities to restructure and reduce costs. | 05/09/2022 |
Creso has executed a Loan Facility Agreement with Health House, whereby Creso will provide a loan up to A$700,000 to Health House for general corporate purposes and working capital. A material use of proceeds from the Facility will be the drafting and completion of a Scheme Implementation Deed and Independent Expert's report. Creso has provided initial funding of A$500,000 to Health House under the terms of the Loan Facility Agreement. | 05/09/2022 |
The company lodges its Appendix 4E Preliminary Final Report. | 01/09/2022 |
The Company requests that the voluntary suspension remain in place until the Company makes an announcement to the market in relation to a material capital raising, which it expects to make pre-market on or before Friday, 9 September 2022. | 23/08/2022 |
Health House International´s German subsidiary, CanPharma, has signed a supply arrangement to access the cannabis extract, dronabinol. Dronabinol is a formulation of pure-THC, the active ingredient in cannabis, that is widely prescribed in Germany. CanPharma will be able to enter framework agreements with statutory health insurance funds on competitive terms. | 18/08/2022 |
The company releases a notice of application for quotation of securities. | 11/08/2022 |
The following securities will be release from ASX imposed escrow on 10 August 2022. The Company will apply for quotation of these securities on 11 August 2022. HHI: 5,562,900 fully paid ordinary shares. | 01/08/2022 |
The company lodges its June 2022 Quarterly Report. | 01/08/2022 |
The company lodges its Appendix 4C Cash Flow Report. | 01/08/2022 |
The Company requests that the voluntary suspension remain in place until the Company makes an announcement to the market in relation to a material capital, which it expects to make pre-market on or before Friday, 19 August 2022. | 29/07/2022 |
Creso Pharma Limited has signed a non-binding term sheet to acquire Health House International Ltd. The non-binding term sheet is conditional upon completion of satisfactory due diligence on Health House and the parties entering into a formal Scheme Implementation Deed, amongst other standard conditions. The acquisition is proposed to be undertaken by a Scheme of Arrangement pursuant to Part 5.1 of the Corporations Act 2001 (Cth). | 29/07/2022 |
The company requests that the voluntary suspension of its securities remain in place until the company makes an announcement to the market in relation to a material capital raising, which it expects to make pre-market on or before 20 July 2022. | 06/07/2022 |
The company releases a notification regarding unquoted securities. | 29/06/2022 |
The company releases a notice of proposed issue of securities. | 27/06/2022 |
Health House International and Zelira Therapeutics have agreed to terminate the scheme of arrangement announced on 23 February 2022. Health House to update the market on alternative strategy in due course. | 22/06/2022 |
The securities of Health House International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HHI, pending the release of an announcement regarding a material capital raising. | 22/06/2022 |
The suspension of trading in the securities of Health House International Limited will be lifted from the commencement of trading on Friday, 16 April 2021, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules | 15/04/2021 |
The company releases the following: Health House Holdings - 2019 Accounts, Health House Holdings - 2020 Accounts, Health House Holdings - Interim Accounts 31 Dec 2020, Securities Trading Policy, Pro Forma Statement of Financial Position, Distribution Schedule, Top 20 Holders, Pre-Quotation Disclosure Notice and Copy of Application for Quotation (Appendix 1A). | 15/04/2021 |
The company releases a prospectus for the offer of up to 17.5 million shares at an issue price of $0.20 each to raise up to $3,500,000 (before costs). | 15/04/2021 |
The company releases the following its Appendix 1A and Information Form and Checklist and Constitution. | 15/04/2021 |
The securities of Health House International Limited are expected to be reinstated to Official Quotation at the commencement of trading at 10:04:30am AEST on Friday, 16 April 2021, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules. HHI raised $3,500,000 pursuant to the offer under its prospectus dated 21 January 2021 ("˜Prospectus') by the issue of 17,500,000 shares at an issue price of $0.20 per share. | 14/04/2021 |
The company lodges its Half Year Accounts. | 31/03/2021 |
name changed from VPCL Limited | 24/03/2021 |
delisted at entity's request under Listing Rule 17.11 | 18/05/2023 |
we understand Creso Pharma Limited acquire all of the issued shares in HHI with HHI shareholders receiving 1 Creso Consideration Share and 0.25 Creso Consideration Options for every 2.9 HHI shares held by them | 18/05/2023 |
The company releases a notice of application for quotation of securities. | 08/05/2023 |
The company releases a notice of proposed issue of securities. | 08/05/2023 |
The securities of Health House International Limited will be suspended from quotation at the close of trading on Friday, 5 May 2023 under Listing Rule 17.2, following lodgement of the Supreme Court of Western Australia orders with ASIC approving the scheme of arrangement by which Creso Pharma Limited will acquire all of the issued shares in HHI. | 05/05/2023 |
The suspension of trading in the securities of Health House International Limited will be lifted from the commencement of trading on Monday, 13 March 2023 following lodgement of its half-year report and Appendix 4D. | 10/03/2023 |
The company lodges its Appendix 4D & FY23 Interim Financial Report. | 10/03/2023 |
The entity's securities will be suspended from quotation under Listing Rule 17.5 from the commencement of trading today, Wednesday, 1 March 2023, for not lodging the relevant periodic report by the due date. If the report is lodged between the closure of the market announcements office yesterday and the imposition of the suspension, the entity's securities will normally be reinstated to quotation on the next trading day after the suspension is imposed. | 01/03/2023 |
The suspension of trading in the securities of Health House International Limited will be lifted from the commencement of trading on Friday, 23 December 2022 following lodgement of its Annual Report to Shareholders and Appendix 4G. | 22/12/2022 |
The company lodges the following: Annual Report to shareholders and Appendix 4G. | 22/12/2022 |
The company lodges its Appendix 4C Cash Flow Report. | 24/11/2022 |
The company lodges its September 2022 Quarterly Report. | 24/11/2022 |
Integration of Health House continues with acquisition to considerably increase revenue. Creso Pharma and Health House International management continue to work towards integration. Funds transferred to relinquish HHI of Zelira debt ahead of acquisition. HHI expected to considerably increase Creso Pharma's revenue profile. Inclusion of HHI's revenue implies a pro forma Creso unaudited last quarter annualized gross revenue (based on 30-Sep-22 quarter) of approximately A$24m (based on Creso revenues and entire quarter of SSH and HHI revenues). Product registration in South Korea underpins international expansion. | 23/11/2022 |
Inclusion of HHI's revenue implies a pro forma Creso unaudited last quarter annualized gross revenue (based on 30-Sep-22 quarter) of approximately A$24m (based on Creso revenues and entire quarter of SSH and HHI revenues). Scheme Implementation Deed signed to acquire Health House International for total value of up to approximately $4.6m, based on a Creso share price of A$0.043 per share. Health House is an international pharmaceutical distributor, specialising in the sale and distribution of medicinal cannabis products across Australia and the UK. Provides Creso Pharma with another revenue generating operating division and considerably increases the Company's global footprint. HHI generated $15,644,524 in revenue during FY22 (ending 30-Jun-22) "“ an 85.1% increase on FY2021 (FY2021: $8,449,564) and a 161.6% rise on FY2020 (FY2020:$5,978,940). Cost reduction opportunities across HHI are apparent "“ Health House is expected to benefit from shared group services, allowing for steep reductions in corporate costs in HHI. HHI recently completed the sale of CanPharma, eliminating an underperforming asset and its associated liabilities "“ removes actual and contingent liabilities of ~€2,887,000 (A$4,456,000) from HHI's balance sheet. Additional cross-selling opportunities, including the import of Mernova Medicinal Inc.'s premium cannabis product to Australia to potentially assist in fast tracking cash flow breakeven. Acquisition reiterates Company strategy of assembling a strategic portfolio of businesses and brands that have complementary strengths across manufacturing, processing, formulation, sales and distribution. Management intends to review further M&A opportunities. | 21/11/2022 |
Zelira Therapeutics y has agreed with Health House Limited and Creso Pharma Limited for the repayment of the previous working capital facility loan that Zelira had provided to Health House as follows: Creso, on behalf of Health House will make an immediate cash payment of $550,000 to Zelira; and Subject to shareholder approval on or prior to 31 December 2022, Creso agrees to issue to Zelira (or its nominee) that number of Creso Shares equal to $800,000 divided by the closing price of Creso's ordinary shares as traded on ASX the day prior to the Shareholder Meeting. Zelira is pleased advise it has now received an amount of $550,000 under this agreement. | 21/11/2022 |
Health House has entered into a scheme implementation deed with Creso Pharma Limited. Creso loan facility increased to $3,400,000. | 21/11/2022 |
The company announces the completion of the sale of CanPharma GmbH to Ms Sabine Jacker following the satisfaction of all conditions precedent. The sale of CanPharma removes actual and contingent liabilities of approx. €2,887,000 (AUD$4,456,000) from the Health House group's balance sheet. The sale of CanPharma will have no impact on the arrangement agreed between Health House and Creso Pharma Limited. | 16/11/2022 |
The company has executed a binding terms sheet with Ms Sabine Jacker for the sale all of the outstanding common shares of wholly-owned German subsidiary CanPharma GmbH. The sale of CanPharma will have no impact on the arrangement agreed between Health House and Creso Pharma Limited. | 01/11/2022 |
The company intends to hold its AGM on 28 November 2022. Any nominations for directors must be received at the company's registered office no later than 5.00pm (Perth time) on 10 October 2022. | 03/10/2022 |
The securities of the company will be suspended from Official Quotation in accordance with Listing Rule 17.5 from the commencement of trading today, 3 October 2022, following their failure to lodge the relevant periodic report by the due date. | 03/10/2022 |
The suspension of trading in the securities of Health House International Limited will be lifted immediately following the release by HHI of an announcement. | 09/09/2022 |
Following execution of the Loan Facility Agreement with Creso Pharma Limited and the Convertible Note, announced on 5 September 2022, the Health House voluntary suspension will be lifted. | 09/09/2022 |
Zelira Therapeutics has agreed with Health House to extend the date for repayment of its short-term loan provided by ZLD in February 2022 to 31 October 2022, subject to Health House paying an amount of $400,000 immediately. Zelira has now received an amount of $400,000 from Health House. The balance of the loan, including calculated interest is now repayable by 31 October 2022, pursuant to the terms of the Zelira working capital facility loan agreement announced to the market on February 24, 2022. | 08/09/2022 |
The company releases an Appendix 3G. | 05/09/2022 |
Creso has significantly advanced its due diligence on the proposed acquisition of Health House. Work to date included an analysis of HHI's revenue base, following HHI's generation of A$15.2m of cash receipts for the 12 months ended 30 June 2022 as well as opportunities to restructure and reduce costs. | 05/09/2022 |
Creso has executed a Loan Facility Agreement with Health House, whereby Creso will provide a loan up to A$700,000 to Health House for general corporate purposes and working capital. A material use of proceeds from the Facility will be the drafting and completion of a Scheme Implementation Deed and Independent Expert's report. Creso has provided initial funding of A$500,000 to Health House under the terms of the Loan Facility Agreement. | 05/09/2022 |
The company lodges its Appendix 4E Preliminary Final Report. | 01/09/2022 |
The Company requests that the voluntary suspension remain in place until the Company makes an announcement to the market in relation to a material capital raising, which it expects to make pre-market on or before Friday, 9 September 2022. | 23/08/2022 |
Health House International´s German subsidiary, CanPharma, has signed a supply arrangement to access the cannabis extract, dronabinol. Dronabinol is a formulation of pure-THC, the active ingredient in cannabis, that is widely prescribed in Germany. CanPharma will be able to enter framework agreements with statutory health insurance funds on competitive terms. | 18/08/2022 |
The company releases a notice of application for quotation of securities. | 11/08/2022 |
The following securities will be release from ASX imposed escrow on 10 August 2022. The Company will apply for quotation of these securities on 11 August 2022. HHI: 5,562,900 fully paid ordinary shares. | 01/08/2022 |
The company lodges its June 2022 Quarterly Report. | 01/08/2022 |
The company lodges its Appendix 4C Cash Flow Report. | 01/08/2022 |
The Company requests that the voluntary suspension remain in place until the Company makes an announcement to the market in relation to a material capital, which it expects to make pre-market on or before Friday, 19 August 2022. | 29/07/2022 |
Creso Pharma Limited has signed a non-binding term sheet to acquire Health House International Ltd. The non-binding term sheet is conditional upon completion of satisfactory due diligence on Health House and the parties entering into a formal Scheme Implementation Deed, amongst other standard conditions. The acquisition is proposed to be undertaken by a Scheme of Arrangement pursuant to Part 5.1 of the Corporations Act 2001 (Cth). | 29/07/2022 |
The company requests that the voluntary suspension of its securities remain in place until the company makes an announcement to the market in relation to a material capital raising, which it expects to make pre-market on or before 20 July 2022. | 06/07/2022 |
The company releases a notification regarding unquoted securities. | 29/06/2022 |
The company releases a notice of proposed issue of securities. | 27/06/2022 |
Health House International and Zelira Therapeutics have agreed to terminate the scheme of arrangement announced on 23 February 2022. Health House to update the market on alternative strategy in due course. | 22/06/2022 |
The securities of Health House International Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of HHI, pending the release of an announcement regarding a material capital raising. | 22/06/2022 |
The suspension of trading in the securities of Health House International Limited will be lifted from the commencement of trading on Friday, 16 April 2021, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules | 15/04/2021 |
The company releases the following: Health House Holdings - 2019 Accounts, Health House Holdings - 2020 Accounts, Health House Holdings - Interim Accounts 31 Dec 2020, Securities Trading Policy, Pro Forma Statement of Financial Position, Distribution Schedule, Top 20 Holders, Pre-Quotation Disclosure Notice and Copy of Application for Quotation (Appendix 1A). | 15/04/2021 |
The company releases a prospectus for the offer of up to 17.5 million shares at an issue price of $0.20 each to raise up to $3,500,000 (before costs). | 15/04/2021 |
The company releases the following its Appendix 1A and Information Form and Checklist and Constitution. | 15/04/2021 |
The securities of Health House International Limited are expected to be reinstated to Official Quotation at the commencement of trading at 10:04:30am AEST on Friday, 16 April 2021, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules. HHI raised $3,500,000 pursuant to the offer under its prospectus dated 21 January 2021 ("˜Prospectus') by the issue of 17,500,000 shares at an issue price of $0.20 per share. | 14/04/2021 |
The company lodges its Half Year Accounts. | 31/03/2021 |
name changed from VPCL Limited | 24/03/2021 |
Your browser may reflect a date of printing in American format.
DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
---|---|---|---|---|---|
21/12/2016 | Russell Francis | 1,000,000 | $0.017 | $17,356 | |
18/03/2015 | John Lester | On market | 100,000 | $0.020 | $2,011 |
18/03/2015 | John Lester | On market | 100,000 | $0.020 | $2,011 |
22/12/2014 | John Lester | On market | 51,000 | $0.020 | $1,020 |
17/12/2014 | Hugh Dai | On market | 340,000 | $0.021 | $7,300 |
NAME | TITLE | DATE OF APPT |
---|---|---|
David Wheeler | Non Exec Chairman | 02/04/2020 |
Christopher Mews | Non Exec Director | 13/07/2018 |
Michael Rann | Non Exec Director | 19/03/2021 |
Tim Slate | Company Secretary |
Date of first appointment, title may have changed.
NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
---|---|---|---|
David Attwood | CEO | 10/08/2021 | 19/03/2023 |
Henrik Sprengel | Executive Director | 10/08/2021 | 16/11/2022 |
Leanne Graham | Non Exec Chairman | 10/10/2015 | 19/03/2021 |
Justin Klintberg | Non Exec Director | 03/04/2018 | 02/04/2020 |
Rhonda Robati | Executive | 01/01/2017 | 17/08/2018 |
Russell Francis | CEO | 22/10/2015 | 13/07/2018 |
Daniel Rohr | Non Exec Director | 10/12/2015 | 03/04/2018 |
Harry Karelis | Non Exec Director | 19/10/2014 | 03/04/2018 |
Glen Moora | Executive Director | 22/10/2015 | 25/10/2016 |
Patrick Connell | Executive Director | 22/10/2015 | 25/10/2016 |
John Lester | Non Exec Chairman | 08/02/2011 | 30/10/2015 |
Noel Halgreen | Non Exec Director | 16/11/2012 | 22/10/2015 |
Hugh Dai | Executive Director, CEO | 08/02/2011 | 22/10/2015 |
Glenn Simpson | CEO | 16/01/2013 | 06/06/2014 |
David Round | CFO | 21/11/2011 | 01/03/2013 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.